Next-Generation Nanobody Targeting EPAS1 and HIF1A for Advanced Cancer Therapy

VHH-P689 is a fully humanized single-domain nanobody developed to target endothelial PAS domain protein 1 (EPAS1) and hypoxia inducible factor 1 subunit alpha (HIF1A). Currently in the Biological Testing development stage, this program addresses key mediators of hypoxia-driven tumorigenesis and adapts innovative antibody engineering as a therapeutic strategy for cancer. By engaging both EPAS1 and HIF1A, VHH-P689 offers the promise of intercepting critical pathways that promote malignant growth and resistance to conventional therapies. The program leverages the unique molecular properties of nanobodies for improved tumor site accessibility, potentially expanding treatment options for various cancer types.

Licensing Opportunity

VHH-P689 is currently open for out-licensing and strategic partnership opportunities. We welcome collaboration with industry and academic partners to accelerate the development and commercialization of this promising anticancer nanobody platform.

Development Phase

Modality

VHH-P689 is designed as a single variable domain nanobody, specifically targeting the PAS-B domain of human hypoxia-inducible factors and HIF-2alpha. The molecule is genetically fused at its N-terminus to a transactivating transcriptional activator, enhancing its functional performance. Expressed efficiently in the Pichia pastoris GS115 strain, the nanobody format offers notable advantages such as a small molecular size, high stability, and superior tissue penetration compared to conventional antibodies. These properties are particularly valuable in cancer therapy, where improved tumor infiltration and rapid systemic distribution can translate to enhanced antitumor activity and optimized pharmacokinetics, addressing key challenges in solid tumor treatment.

Target

EPAS1 and HIF1A are both transcription factors in the hypoxia-inducible factor family, pivotal for mediating cellular responses to low oxygen. EPAS1 (also known as HIF-2alpha) and HIF1A (HIF-1alpha) regulate gene expression programs that support tumor survival, angiogenesis, and metastasis in hypoxic tumor microenvironments. They are mainly expressed in a wide variety of tissues and are especially upregulated in solid tumors and the surrounding stroma. Aberrant activation of EPAS1 and HIF1A is implicated in cancer progression, therapeutic resistance, and poor prognosis, making them high-value targets in oncology. By selectively antagonizing EPAS1 and HIF1A, VHH-P689 arms oncologists with a targeted approach to disrupt fundamental hypoxia-driven processes, thus holding significant potential as a differentiated and strategic asset in cancer drug development.

Mechanism of Action

VHH-P689 functions by binding with high specificity to EPAS1 and HIF1A, inhibiting their activity as key transcriptional regulators under hypoxic conditions. This antagonism disrupts adaptive gene expression that supports cancer cell survival, angiogenesis, and metabolic reprogramming in solid tumors. Through targeting the core hypoxia signaling cascade, VHH-P689 can undermine mechanisms of tumor progression and therapeutic resistance. The modular nanobody format of VHH-P689 also provides a versatile platform for further development, including conjugation with cytotoxic payloads for ADCs or molecular fusion with other domains for bispecific applications, offering strong potential for pipeline expansion in precision oncology.

Cancer

Cancer remains one of the foremost global health challenges, accounting for significant morbidity and mortality worldwide. Cancers arise from a complex interplay of genetic, epigenetic, and environmental factors, often presenting late and progressing rapidly. Standard care currently encompasses surgery, radiotherapy, chemotherapy, immunotherapy, and targeted biological agents. While advances in targeted therapies and immuno-oncology have improved outcomes for certain patients, many tumors exhibit intrinsic or acquired resistance, often associated with hypoxic microenvironments and activation of survival pathways such as those regulated by EPAS1 and HIF1A. There remains a pressing medical need for innovative therapeutics that can effectively address tumor hypoxia and overcome the limitations of current modalities. VHH-P689, by targeting critical regulators of the hypoxic response, represents a novel approach with potential to improve outcomes across a wide spectrum of cancer types.